Key takeaway
Innovent Biologics has entered a global strategic collaboration with Pfizer, under which Innovent Biologics will receive an upfront payment of USD650mn and will be eligible for up to USD9.85bn in development, regulatory, and commercialization milestone payments, bringing the total deal value to USD10.5bn. In addition, for each approved product, Innovent Biologics will receive sales royalties of up to a double-digit percentage. The agreement covers multiple collaboration models, including licensing, co-development, and co-commercialization (Co-Co). This collaboration combines Innovent Biologics’s innovation capabilities in new drug discovery and early clinical development with Pfizer’s comprehensive strengths in global R&D and commercialization. Through global co-development of core programs and co-commercialization in the US and Europe, it will further expand Innovent Biologics’s global footprint. This marks another major milestone in Innovent Biologics’s globalization following its strategic collaborations with Takeda and Eli Lilly, entering the high-profit markets in the US and Europe through the Co-Co model and establishing a clear pathway for global expansion by leveraging partners.
Event
On May 29, 2026, Innovent Biologics entered into a global strategic collaboration with Pfizer, under which Innovent Biologics will receive an upfront payment of USD650mn and will be eligible for up to USD9.85bn in development, regulatory, and commercialization milestone payments, bringing the total deal value to USD10.5bn. In addition, for each approved product, Innovent Biologics will receive sales royalties of up to a double-digit percentage. The agreement covers multiple collaboration models, including licensing, co-development, and co-commercialization (Co-Co). The collaboration covers multiple antibody-drug conjugates (ADCs) with novel differentiated payloads, as well as multispecific antibodies with differentiated immunomodulatory properties and unique structural designs. It consists of 12 programs, including eight early-stage pipelines from Innovent Biologics and four new (de novo) programs proposed by Pfizer.
Comments
Innovent Biologics forms strategic collaboration with Pfizer: Entering the US and European markets through the Co-Co model
Total collaboration value reaches up to USD10.5bn, covering multiple cooperation models including licensing, co-development, and co-commercialization. Innovent Biologics has entered a global strategic collaboration with Pfizer, under which Innovent Biologics will receive an upfront payment of USD650mn and will be eligible for up to USD9.85bn in development, regulatory, and commercialization milestone payments, bringing the total deal value to USD10.5bn. In addition, for each approved product, Innovent Biologics will receive sales royalties of up to a double-digit percentage. The agreement covers multiple collaboration models, including licensing, co-development, and co-commercialization (Co-Co). This marks another major milestone in Innovent Biologics’s globalization following its strategic collaborations with Takeda and Eli Lilly.
The collaboration asset portfolio covers ADCs and multispecific antibodies, fully leveraging the complementary strengths and resources of both parties. This collaboration covers multiple antibody-drug conjugates (ADCs) with novel differentiated payloads, as well as multispecific antibodies featuring differentiated immune regulatory properties and unique structural designs. It consists of 12 programs, including eight early-stage pipelines from Innovent Biologics and four new (de novo) programs proposed by Pfizer. Among them,
INNOVENT BIO and Pfizer will jointly develop four key programs globally and share development costs. Meanwhile, the two parties will jointly commercialize these programs in the United States and Europe and share profits. Meanwhile, Innovent Biologics retains the rights in the Greater China region;
Innovent Biologics grants Pfizer exclusive licenses for four programs outside the Greater China region, with Pfizer bearing the majority of development costs;
Innovent Biologics grants Pfizer global exclusive licenses for four programs, with Pfizer bearing global development costs.
The collaboration between Pfizer and Innovent Biologics adopts the co-development (Co-Co) model, which Pfizer rarely uses, fully demonstrating Pfizer’s trust in Innovent Biologics’s R&D capabilities. In recent years, when conducting large-scale transactions, Pfizer has tended to directly acquire assets or buy out rights, while deep co-development collaborations have been very rare. This choice of joint development fully reflects Pfizer’s recognition of Innovent Biologics’s oncology pipeline and R&D strength; Innovent Biologics will also leverage Pfizer’s global platform to accelerate the internationalization of its pipeline. The two sides’ strengths in R&D and commercialization are highly complementary, breaking the boundaries of traditional licensing collaborations and demonstrating strong mutual confidence in each other’s overall capabilities, pipeline potential, and long-term synergy value.